https://investingnews.com/relay-therapeutics-announces-efficacy-subset-analysis-of-zovegalisib-fulvestrant-in-breast-cancer-patients-pre-treated-with-serd-or-with-esr1-mutations-at-sabcs-2025/
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib + Fulvestrant in Breast Cancer...
Dec 12, 2025 - Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset...